JP2017524721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017524721A5 JP2017524721A5 JP2017507973A JP2017507973A JP2017524721A5 JP 2017524721 A5 JP2017524721 A5 JP 2017524721A5 JP 2017507973 A JP2017507973 A JP 2017507973A JP 2017507973 A JP2017507973 A JP 2017507973A JP 2017524721 A5 JP2017524721 A5 JP 2017524721A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- weeks
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 13
- 239000000935 antidepressant agent Substances 0.000 claims 10
- 230000006698 induction Effects 0.000 claims 10
- 230000001430 anti-depressive effect Effects 0.000 claims 9
- 229940005513 antidepressants Drugs 0.000 claims 9
- 208000024891 symptom Diseases 0.000 claims 5
- 230000003778 catagen phase Effects 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000025307 bipolar depression Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000037326 chronic stress Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462037374P | 2014-08-14 | 2014-08-14 | |
| US62/037,374 | 2014-08-14 | ||
| PCT/US2015/045071 WO2016025721A1 (en) | 2014-08-14 | 2015-08-13 | Methods of treating depression using nmda modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076468A Division JP2020128391A (ja) | 2014-08-14 | 2020-04-23 | Ｎｍｄａ調節剤を使用するうつ病の治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017524721A JP2017524721A (ja) | 2017-08-31 |
| JP2017524721A5 true JP2017524721A5 (enExample) | 2018-09-20 |
Family
ID=55304631
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507973A Pending JP2017524721A (ja) | 2014-08-14 | 2015-08-13 | Ｎｍｄａ調節剤を使用するうつ病の治療方法 |
| JP2020076468A Pending JP2020128391A (ja) | 2014-08-14 | 2020-04-23 | Ｎｍｄａ調節剤を使用するうつ病の治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076468A Pending JP2020128391A (ja) | 2014-08-14 | 2020-04-23 | Ｎｍｄａ調節剤を使用するうつ病の治療方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20170296616A1 (enExample) |
| EP (1) | EP3180015A4 (enExample) |
| JP (2) | JP2017524721A (enExample) |
| KR (1) | KR20170040351A (enExample) |
| CN (1) | CN106659763A (enExample) |
| AU (2) | AU2015301650A1 (enExample) |
| BR (1) | BR112017002930A2 (enExample) |
| CA (1) | CA2957937A1 (enExample) |
| CL (1) | CL2017000378A1 (enExample) |
| CO (1) | CO2017002356A2 (enExample) |
| IL (1) | IL250557A0 (enExample) |
| MX (1) | MX2017002052A (enExample) |
| PH (1) | PH12017500275A1 (enExample) |
| RU (1) | RU2017107033A (enExample) |
| SG (2) | SG10201810016XA (enExample) |
| UA (1) | UA123623C2 (enExample) |
| WO (1) | WO2016025721A1 (enExample) |
| ZA (1) | ZA201701526B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3362080A1 (en) * | 2015-10-16 | 2018-08-22 | Northwestern University | Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder |
| US10487055B2 (en) | 2016-06-01 | 2019-11-26 | Rhode Island Board Of Education | Diindole compounds useful in treatment of nervous system disorders |
| US11358935B2 (en) | 2016-11-28 | 2022-06-14 | Biohaven Pharmaceutical Holding Company Ltd. | Prodrugs of lanicemine and their method of use |
| WO2018234568A2 (en) * | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | Hydroxynorketamine for the use in the treatment of depression |
| WO2019094676A1 (en) * | 2017-11-10 | 2019-05-16 | Naurex Inc. | Methods of administration of nmda receptor agonists |
| EP3720464A1 (en) * | 2017-12-05 | 2020-10-14 | Naurex Inc. | Nmda receptor modulators (rapastinel) combination for use in combined treatment (sleep and cns disorder) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| HRP20140784T1 (hr) * | 2009-10-05 | 2014-10-10 | Northwestern University | Glyx-13 za uporabu u postupku tretiranja refraktornih depresija |
| US9737531B2 (en) * | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
-
2015
- 2015-08-13 RU RU2017107033A patent/RU2017107033A/ru not_active Application Discontinuation
- 2015-08-13 AU AU2015301650A patent/AU2015301650A1/en not_active Abandoned
- 2015-08-13 MX MX2017002052A patent/MX2017002052A/es unknown
- 2015-08-13 SG SG10201810016XA patent/SG10201810016XA/en unknown
- 2015-08-13 CN CN201580043626.3A patent/CN106659763A/zh active Pending
- 2015-08-13 JP JP2017507973A patent/JP2017524721A/ja active Pending
- 2015-08-13 UA UAA201702145A patent/UA123623C2/uk unknown
- 2015-08-13 KR KR1020177006761A patent/KR20170040351A/ko not_active Ceased
- 2015-08-13 EP EP15832514.2A patent/EP3180015A4/en not_active Withdrawn
- 2015-08-13 BR BR112017002930A patent/BR112017002930A2/pt not_active IP Right Cessation
- 2015-08-13 WO PCT/US2015/045071 patent/WO2016025721A1/en not_active Ceased
- 2015-08-13 CA CA2957937A patent/CA2957937A1/en not_active Abandoned
- 2015-08-13 US US15/503,840 patent/US20170296616A1/en not_active Abandoned
- 2015-08-13 SG SG11201701134XA patent/SG11201701134XA/en unknown
-
2017
- 2017-02-12 IL IL250557A patent/IL250557A0/en unknown
- 2017-02-14 CL CL2017000378A patent/CL2017000378A1/es unknown
- 2017-02-14 PH PH12017500275A patent/PH12017500275A1/en unknown
- 2017-03-01 ZA ZA2017/01526A patent/ZA201701526B/en unknown
- 2017-03-10 CO CONC2017/0002356A patent/CO2017002356A2/es unknown
-
2020
- 2020-04-23 JP JP2020076468A patent/JP2020128391A/ja active Pending
- 2020-05-15 AU AU2020203165A patent/AU2020203165A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017524721A5 (enExample) | ||
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| JP2015187125A5 (enExample) | ||
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| JP2017031213A5 (enExample) | ||
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| JP2015512418A5 (enExample) | ||
| RU2017107033A (ru) | Способы лечения депрессии с применением модуляторов nmda | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| RU2014141893A (ru) | Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких | |
| JP2016532516A5 (enExample) | ||
| RU2016149316A (ru) | Лечение ревматоидного артрита | |
| IL309340A (en) | Dosing regimen for missing doses of paliperidone long-acting injectable esters | |
| JP2017533220A5 (enExample) | ||
| MY204827A (en) | Semaglutide in medical therapy | |
| MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
| HRP20201388T1 (hr) | Režimi i postupci liječenja multiple skleroze uporabom ofatumumaba | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| TN2015000480A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| JP2016505050A5 (enExample) | ||
| HRP20240812T1 (hr) | Oblici doziranja i terapijska primjena l-4-klorokinurenina | |
| JP2019507786A5 (enExample) | ||
| WO2017142871A8 (en) | Methods comprising fixed intermittent dosing of cediranib | |
| JP2016504361A5 (enExample) | ||
| MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. |